Phase 1CompletedINTERVENTIONAL
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
ClinicalTrials.gov · NCT04903509 · Registry updated: 2022-08-31
- Condition / research focus
- Healthy
- Sponsor
- Boehringer Ingelheim
- Countries with listed sites
- Germany
- Registry dates and results
- Start: 2021-06-08. Completion: 2022-08-26 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- BI 1820237 (drug)
- Placebo (drug)
- Saxenda® (drug) — also listed as: Liraglutide
- Paracetamol-ratiopharm® (drug) — also listed as: Paracetamol
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.